NewLimit Raises $435 Million Series C to Advance Epigenetic Reprogramming Platform Targeting Age-Related Disease
2 weeks ago
In
Clinical Trials
Deals
Investments
Partnerships
Setrusumab Trial Update Disappoints Investors Despite Continued Clinical Progress
12 months ago
In
Investments
Venture Capital
aTyr Pharma Added to Russell 2000® and Russell 3000® Indexes, Reflecting Growth and Market Confidence
12 months ago
In
Biopharma Highlights
Innovation
Investments
People
Pharma Industry Updates
Oncolytics Biotech Highlights Growing Investor Interest as Global Oncology Drug Market Surpasses $900 Billion Forecast
12 months ago
In
Biopharma Highlights
Clinical Trials
Innovation
Investments
Go to Inverstment
